Pancreatic neuroendocrine tumor

Summary

Pancreatic neuroendocrine tumor (MONDO:0019954) is a cancer (an umbrella term covering 11 Mondo subtypes) with 2 cohort genes (2 CIViC-evidence somatic drivers; 2 ClinVar predisposition records) and 93 clinical trials. Top therapeutic interventions include everolimus, cabozantinib, and octreotide.

At a glance

• Classification: Cancer
• Prevalence: 1-9 / 100 000 (Japan) [Orphanet-validated]
• Umbrella term: 11 Mondo subtypes
• Cohort genes: 2
• ClinVar variants: 2
• Clinical trials: 93

Clinical features

Epidemiology

Prevalence records

7 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 1 000 000	0.21	Europe	Validated
Annual incidence	1-9 / 1 000 000	0.22	United States	Validated
Annual incidence	1-9 / 100 000	1.27	Japan	Validated
Annual incidence	1-9 / 1 000 000	0.21	France	Validated
Point prevalence	1-9 / 100 000	2.69	Japan	Validated
Point prevalence	1-5 / 10 000	27.5	United States	Validated
Point prevalence	1-5 / 10 000		Europe	Not yet validated

Identifiers

Disease identifiers

Field	Value
Canonical name	pancreatic neuroendocrine tumor
Mondo ID	MONDO:0019954
EFO	EFO:1000045
Orphanet	97253
NCIT	C27720
UMLS	C1337011
MedGen	277875
GARD	0013034
Is cancer (heuristic)	yes

Also known as: islet cell tumor · islet cell tumors - pancreas · islet cell tumors of the pancreas · islet cell tumour · islet cell tumours - pancreas · islet cell tumours of the pancreas · neuroendocrine tumour of pancreas · pancreatic endocrine tumor · pancreatic endocrine tumour · pancreatic NET · pancreatic neuroendocrine tumor · PANET · well differentiated pancreatic endocrine neoplasm · well differentiated pancreatic endocrine tumor · well differentiated pancreatic endocrine tumour · well-differentiated NEN of pancreas · well-differentiated neuroendocrine neoplasm of pancreas · well-differentiated pancreatic NEN · well-differentiated pancreatic neuroendocrine neoplasm

Data availability: 2 ClinVar variants · 1 cell line · 10 intOGen driver records.

Disease family

An umbrella term covering 11 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system neuroendocrine neoplasm › digestive system neuroendocrine tumor, grade 1/2 › pancreatic neuroendocrine tumor

Related subtypes (9): small intestine neuroendocrine tumor, well differentiated, low or intermediate grade, gastrin-producing neuroendocrine tumor, esophageal neuroendocrine tumor, L-cell glucagon-like peptide-producing neuroendocrine tumor, gastric neuroendocrine tumor, well differentiated, low or intermediate grade, neuroendocrine tumor of the colon, well differentiated, low or intermediate grade tumor, rectal neuroendocrine tumor, gallbladder neuroendocrine tumor, grade 1/2, intestinal neuroendocrine tumor G1

Subtypes (11): pancreatic delta cell neuroendocrine tumor, pancreatic gastrin-producing neuroendocrine tumor, non-functional pancreatic neuroendocrine tumor, pancreatic insulin-producing neuroendocrine tumor, somatostatinoma, GRFoma, PPoma, glucagonoma, VIPoma, pancreatic neuroendocrine tumor G1, functional pancreatic neuroendocrine tumor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

2 retrieved; paginated sample, class counts are floors:

2 pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
52925	NM_000059.4(BRCA2):c.994dup (p.Ile332fs)	BRCA2	Pathogenic	reviewed by expert panel
560018	NM_024675.4(PALB2):c.778C>T (p.Gln260Ter)	PALB2	Pathogenic	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 17 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
BRCA2	LoF	BLCA,BRCA,CESC,CHOL,HCC,HNSC,LUSC,MBL,OVT,PAAD,PRAD,PROSTATE,RCC,VULVA	CIViC #7
PALB2	LoF	OVT	CIViC #15013

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
BRCA2	Orphanet:1331	Familial prostate cancer
BRCA2	Orphanet:1333	Familial pancreatic carcinoma
BRCA2	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
BRCA2	Orphanet:178	Chordoma
BRCA2	Orphanet:227535	Hereditary breast cancer
BRCA2	Orphanet:319462	Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations
BRCA2	Orphanet:440437	Familial colorectal cancer Type X
BRCA2	Orphanet:654	Nephroblastoma
BRCA2	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
BRCA2	Orphanet:694963	Inflammatory breast cancer
BRCA2	Orphanet:70567	Cholangiocarcinoma
BRCA2	Orphanet:84	Fanconi anemia
PALB2	Orphanet:1333	Familial pancreatic carcinoma
PALB2	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
PALB2	Orphanet:178	Chordoma
PALB2	Orphanet:227535	Hereditary breast cancer
PALB2	Orphanet:84	Fanconi anemia

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
BRCA2	HGNC:1101	ENSG00000139618	P51587	Breast cancer type 2 susceptibility protein	clinvar
PALB2	HGNC:26144	ENSG00000083093	Q86YC2	Partner and localizer of BRCA2	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
BRCA2	Breast cancer type 2 susceptibility protein	Involved in double-strand break repair and/or homologous recombination.
PALB2	Partner and localizer of BRCA2	Plays a critical role in homologous recombination repair (HRR) through its ability to recruit BRCA2 and RAD51 to DNA breaks.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Scaffold/PPI	1	8.6×	0.225
Other/Unknown	1	0.9×	0.805

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
BRCA2	Other/Unknown	no		BRCA2_repeat, NA-bd_OB-fold, BRCA2_OB_1
PALB2	Scaffold/PPI	no		WD40/YVTN_repeat-like_dom_sf, PALB2_WD40, WD40_repeat_dom_sf

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
secondary oocyte	2
male germ line stem cell (sensu Vertebrata) in testis	1
ventricular zone	1
buccal mucosa cell	1
oocyte	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
BRCA2	184	ubiquitous	marker	male germ line stem cell (sensu Vertebrata) in testis, secondary oocyte, ventricular zone
PALB2	232	ubiquitous	yes	secondary oocyte, buccal mucosa cell, oocyte

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
PALB2	5,641
BRCA2	4,839

Intra-cohort edges

A	B	Sources
BRCA2	PALB2	biogrid_interaction, intact, string_interaction

Structural data

PDB: 2 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
BRCA2	P51587	14
PALB2	Q86YC2	4

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 29. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Impaired BRCA2 binding to PALB2	2	456.8×	3e-05	BRCA2, PALB2
Defective homologous recombination repair (HRR) due to BRCA1 loss of function	2	423.0×	3e-05	BRCA2, PALB2
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function	2	423.0×	3e-05	BRCA2, PALB2
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function	2	423.0×	3e-05	BRCA2, PALB2
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	2	393.8×	3e-05	BRCA2, PALB2
Homologous DNA Pairing and Strand Exchange	2	380.7×	3e-05	BRCA2, PALB2
Resolution of D-loop Structures through Holliday Junction Intermediates	2	300.5×	4e-05	BRCA2, PALB2
HDR through Homologous Recombination (HRR)	2	190.3×	1e-04	BRCA2, PALB2
Impaired BRCA2 translocation to the nucleus	1	1903.3×	0.002	BRCA2
Impaired BRCA2 binding to SEM1 (DSS1)	1	1903.3×	0.002	BRCA2
Defective homologous recombination repair (HRR) due to PALB2 loss of function	1	475.8×	0.005	BRCA2
HDR through MMEJ (alt-NHEJ)	1	439.2×	0.005	BRCA2
Diseases of DNA Double-Strand Break Repair	1	407.9×	0.005	BRCA2
Defective homologous recombination repair (HRR) due to BRCA2 loss of function	1	407.9×	0.005	BRCA2
Resolution of D-Loop Structures	1	317.2×	0.006	BRCA2
Diseases of DNA repair	1	285.5×	0.006	BRCA2
Homology Directed Repair	1	154.3×	0.010	BRCA2
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)	1	154.3×	0.010	BRCA2
Impaired BRCA2 binding to RAD51	1	154.3×	0.010	BRCA2
Meiosis	1	142.8×	0.010	BRCA2
Presynaptic phase of homologous DNA pairing and strand exchange	1	135.9×	0.010	BRCA2
DNA Double-Strand Break Repair	1	124.1×	0.011	BRCA2
Reproduction	1	95.2×	0.013	BRCA2
Meiotic recombination	1	64.9×	0.019	BRCA2
KEAP1-NFE2L2 pathway	1	60.1×	0.019	PALB2
DNA Repair	1	49.2×	0.023	BRCA2
Neddylation	1	23.7×	0.045	PALB2
Cell Cycle	1	18.0×	0.057	BRCA2
Disease	1	6.5×	0.147	BRCA2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
inner cell mass cell proliferation	2	991.3×	3e-05	BRCA2, PALB2
double-strand break repair via homologous recombination	2	156.0×	7e-04	BRCA2, PALB2
mitotic recombination-dependent replication fork processing	1	4213.0×	0.003	BRCA2
negative regulation of mammary gland epithelial cell proliferation	1	1685.2×	0.005	BRCA2
establishment of protein localization to telomere	1	1053.2×	0.007	BRCA2
response to UV-C	1	842.6×	0.007	BRCA2
telomere maintenance via recombination	1	766.0×	0.007	BRCA2
regulation of DNA damage checkpoint	1	561.7×	0.007	BRCA2
centrosome duplication	1	468.1×	0.007	BRCA2
response to X-ray	1	443.5×	0.007	BRCA2
female gonad development	1	401.2×	0.007	BRCA2
post-anal tail morphogenesis	1	366.4×	0.007	PALB2
hematopoietic stem cell proliferation	1	324.1×	0.007	BRCA2
oocyte maturation	1	300.9×	0.007	BRCA2
male meiosis I	1	290.6×	0.007	BRCA2
response to gamma radiation	1	290.6×	0.007	BRCA2
mesoderm development	1	263.3×	0.007	PALB2
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	1	247.8×	0.007	BRCA2
embryonic organ development	1	240.7×	0.007	PALB2
positive regulation of mitotic cell cycle	1	234.1×	0.007	BRCA2
regulation of cytokinesis	1	210.7×	0.008	BRCA2
cellular response to ionizing radiation	1	205.5×	0.008	BRCA2
nucleotide-excision repair	1	191.5×	0.008	BRCA2
somitogenesis	1	187.2×	0.008	PALB2
DNA damage response, signal transduction by p53 class mediator	1	179.3×	0.008	BRCA2
cellular senescence	1	147.8×	0.009	BRCA2
double-strand break repair	1	101.5×	0.013	BRCA2
animal organ morphogenesis	1	95.8×	0.013	PALB2
multicellular organism growth	1	68.5×	0.018	PALB2
brain development	1	39.8×	0.029	BRCA2

Therapeutics

Drugs indicated for this disease

3 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Belzutifan	Approved (phase 4)
Everolimus	Approved (phase 4)
Sunitinib	Approved (phase 4)
Capecitabine	Phase 3 (in late-stage trials)
Octreotide	Phase 3 (in late-stage trials)
Somatostatin	Phase 3 (in late-stage trials)
Surufatinib	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Abemaciclib, Dacarbazine, Dactolisib, Metformin, Palbociclib, Tegafur, Temozolomide, Thalidomide.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 2

Druggability breadth: 0 of 2 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
BRCA2	0	0
PALB2	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

0 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	2	BRCA2, PALB2

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
BRCA2	0	—
PALB2	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 93.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	37
PHASE2	30
PHASE1	17
PHASE3	3
PHASE1/PHASE2	3
PHASE2/PHASE3	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02842749	PHASE4	COMPLETED	Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
NCT03375320	PHASE3	ACTIVE_NOT_RECRUITING	Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
NCT05477576	PHASE3	RECRUITING	Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
NCT06943755	PHASE2/PHASE3	RECRUITING	Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT07591493	PHASE3	NOT_YET_RECRUITING	Adjuvant Trial in Pancreatic Neuroendocrine Tumors
NCT00227617	PHASE2/PHASE3	TERMINATED	Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
NCT03074513	PHASE2	ACTIVE_NOT_RECRUITING	Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
NCT03600233	PHASE2	ACTIVE_NOT_RECRUITING	Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
NCT03891784	PHASE2	ACTIVE_NOT_RECRUITING	Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
NCT04924075	PHASE2	RECRUITING	Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
NCT05040360	PHASE2	RECRUITING	Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
NCT05247905	PHASE2	ACTIVE_NOT_RECRUITING	Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
NCT05988918	PHASE2	ACTIVE_NOT_RECRUITING	Multicenter Trial of ESK981 in Patients With Select Solid Tumors
NCT05997056	PHASE2	RECRUITING	Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
NCT06158516	PHASE2	NOT_YET_RECRUITING	A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
NCT07121478	PHASE2	ENROLLING_BY_INVITATION	Patients With High-grade Pancreatic Neuroendocrine Tumors
NCT00017199	PHASE2	COMPLETED	PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
NCT00019786	PHASE2	COMPLETED	Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases
NCT00027638	PHASE2	COMPLETED	Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
NCT00416767	PHASE2	COMPLETED	Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
NCT00427349	PHASE2	COMPLETED	AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
NCT00434109	PHASE2	COMPLETED	Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
NCT00466856	PHASE2	TERMINATED	Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
NCT00576680	PHASE1/PHASE2	COMPLETED	RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
NCT00602082	PHASE2	COMPLETED	Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
NCT00947167	PHASE2	TERMINATED	A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
NCT01024387	PHASE2	COMPLETED	AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
NCT01121562	PHASE2	COMPLETED	Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
NCT01229943	PHASE2	COMPLETED	Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
NCT01374451	PHASE2	TERMINATED	Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
NCT01466036	PHASE2	COMPLETED	Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
NCT01648465	PHASE2	TERMINATED	Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
NCT02038738	PHASE1/PHASE2	UNKNOWN	68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
NCT02294006	PHASE2	UNKNOWN	Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs
NCT02575300	PHASE2	COMPLETED	Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
NCT03204019	PHASE2	UNKNOWN	A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor
NCT04505553	PHASE2	COMPLETED	Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
NCT05568017	PHASE2	TERMINATED	Neoadjuvant PRRT With Y-90-DOTATOC in pNET
NCT05610826	PHASE1/PHASE2	WITHDRAWN	Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
NCT04119024	PHASE1	RECRUITING	Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
EVEROLIMUS	4	9
CABOZANTINIB	4	5
OCTREOTIDE	4	5
LUTETIUM OXODOTREOTIDE LU-177	4	3
SUNITINIB	4	3
ABEMACICLIB	4	1
BELZUTIFAN	4	1
BEVACIZUMAB	4	1
INDIUM IN 111 PENTETREOTIDE	4	1
LANREOTIDE	4	1
LEUCOVORIN	4	1
OXALIPLATIN	4	1
PASIREOTIDE	4	1
PERTUZUMAB	4	1
STREPTOZOCIN	4	1
TEGAFUR	4	1
ACTINIUM AC 225 DOTATATE	3	1
EVOFOSFAMIDE	3	1
INCOMPLETE FREUND’S ADJUVANT	3	1
SURUFATINIB	3	1
ZANZALINTINIB	3	1
EDOTREOTIDE YTTRIUM Y-90	2	2
FOSLINANIB	2	1
SAPANISERTIB	2	1
SVN53-67/M57-KLH PEPTIDE VACCINE	2	1
ZENIDOLOL	2	1
PAC-1	1	1
CHEMBL3350037	0	2
CHEMBL4079877	0	1
CHEMBL4525833	0	1